Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Total Non-Current Liabilities (2016 - 2025)

Sanofi's Total Non-Current Liabilities history spans 11 years, with the latest figure at $31.1 billion for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 13.04% year-over-year to $31.1 billion; the TTM value through Dec 2025 reached $31.1 billion, up 13.04%, while the annual FY2025 figure was $30.2 billion, 8.32% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $31.1 billion at Sanofi, up from $27.5 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $34.2 billion in Q4 2021 and bottomed at $27.5 billion in Q4 2024.
  • The 5-year median for Total Non-Current Liabilities is $30.0 billion (2023), against an average of $30.2 billion.
  • The largest annual shift saw Total Non-Current Liabilities decreased 17.73% in 2022 before it increased 13.04% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $34.2 billion in 2021, then fell by 17.73% to $28.2 billion in 2022, then grew by 6.64% to $30.0 billion in 2023, then dropped by 8.25% to $27.5 billion in 2024, then rose by 13.04% to $31.1 billion in 2025.
  • Per Business Quant, the three most recent readings for SNY's Total Non-Current Liabilities are $31.1 billion (Q4 2025), $27.5 billion (Q4 2024), and $30.0 billion (Q4 2023).